Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elan up on extended debt deadline

ELN was up $0.72 (18%) to $4.77 on 7.1 million shares on Wednesday on news that it

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE